AstraZeneca PLC Director Declaration (7241O)
October 03 2019 - 11:00AM
UK Regulatory
TIDMAZN
RNS Number : 7241O
AstraZeneca PLC
03 October 2019
3 October 2019 16:00 BST
Director Declaration
AstraZeneca PLC (the Company) today announced, pursuant to
Listing Rule 9.6.14 R (2), that Pascal Soriot, Chief Executive
Officer of the Company, is a director of Viela Bio, Inc. which
recently completed an initial public offering and listed on the
Nasdaq Global Market.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company
that focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three therapy areas - Oncology, Cardiovascular, Renal and
Metabolism (CVRM), and Respiratory. AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and follow us on
Twitter @AstraZeneca.
Media Relations
Gonzalo Viña +44 203 749 5916
Rob Skelding Oncology +44 203 749 5821
Rebecca Einhorn Oncology +1 301 518 4122
Matt Kent BioPharmaceuticals +44 203 749 5906
Jennifer Hursit Other +44 203 749 5762
Christina Malmberg Hägerstrand Sweden +46 8 552 53 106
Michele Meixell US +1 302 885 2677
Investor Relations
Thomas Kudsk Larsen +44 203 749 5712
Henry Wheeler Oncology +44 203 749 5797
Christer Gruvris BioPharmaceuticals (CV, metabolism) +44 203 749 5711
Nick Stone BioPharmaceuticals (respiratory, renal) +44 203 749 5716
Josie Afolabi Other medicines +44 203 749 5631
Craig Marks Finance, fixed income +44 7881 615 764
Jennifer Kretzmann Corporate access, retail investors +44 203 749 5824
US toll-free +1 866 381 72 77
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RDNZXLFBKBFZFBQ
(END) Dow Jones Newswires
October 03, 2019 11:00 ET (15:00 GMT)
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2023 to Mar 2024